Compare ACADIA Pharmaceuticals Inc. (ACAD) vs A O Smith Corp (AOS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs A O Smith Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while A O Smith Corp trades at $59.78 (market cap $8.45B). The key difference: A O Smith Corp is the larger of the two by market cap, and A O Smith Corp pays a 2.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AOS | |
|---|---|---|
Market Cap | $4.49B | $8.45B |
Sector | Health | Industrials |
52-Week High | $28.06 | $80.47 |
52-Week Low | $20.06 | $55.78 |
Enterprise Value | $3.69B | $8.90B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
A.O. Smith (AOS) trades at $61.31, down 2.25% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a Q1 2026 earnings miss ($0.85 actual vs. $0.94 expected) but maintains strong profitability with a 13.84% net margin and 28.27% ROE. Recent leadership changes include CEO Stephen Shafer becoming chairman as of July 1, 2026 (PRNewswire, June 22, 2026).
The stock shows mixed signals: solid fundamentals and a $68 consensus price target suggest upside, but recent earnings weakness and repeated Zacks Strong Sell ratings (June 18, 2026) indicate near-term headwinds. Investors face risks from China market softness and competitive pressures, though cash flow stability and dividend payments provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →
